SciSparc
Open
$8.38
Prev. Close
$8.38
High
$8.38
Low
$7.88
Market Snapshot
$478.18K
-0.1
-1.51
3
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Recently from Cashu
Adaptability and Innovation: SciSparc's Path in the Evolving Cannabis Industry
Navigating the Evolution of the Cannabis Industry: A Call for Adaptability and Innovation The cannabis industry is currently undergoing a transformative phase as legalization spreads across various re…
SciSparc's Strategic Adaptation in the Transforming Cannabis Market Landscape
Navigating the Evolving Cannabis Landscape: A Call for Innovation and Adaptability The cannabis industry is experiencing a transformative phase as it adapts to newfound market opportunities following…